Baig Sahar, Vanarsa Kamala, Ding Huihua, Titus Anto Sam Crosslee Louis Sam, McMahon Maureen, Mohan Chandra
Department of Biomedical Engineering, University of Houston, Houston, TX, United States.
Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, United States.
Front Cardiovasc Med. 2022 May 16;9:861724. doi: 10.3389/fcvm.2022.861724. eCollection 2022.
Systemic lupus erythematosus (SLE) is associated with an increased incidence of acute and chronic cardiovascular disease as compared to the general population. This study uses a comprehensive metabolomic screen of baseline sera from lupus patients to identify metabolites that predict future carotid plaque progression, following 8-9 years of follow-up. Nine patients had SLE without plaque progression, 8 had SLE and went on to develop atherosclerotic plaques (SLE), and 8 patients were controls who did not have SLE. The arachidonic acid pathway metabolites, leukotriene B4 (LTB4) and 5-hydroxyeicosatetraenoic acid (5-HETE), and the oxidized lipids 9/13-hydroxyoctodecadienoic acid (HODE) were found to be significantly altered ( < 0.05 and fold-change >2) in SLE patients compared to SLE patients without plaque progression. SLE patients also exhibited significantly altered levels of branched chain amino acid (BCAA) metabolites and plasmalogens compared to the non-SLE controls. Taken together with the rich literature on these metabolites, these findings suggest that the identified metabolites may not only be prognostic of cardiovascular disease development in SLE patients, but they may also be active drivers of atheroma formation. Early identification of these high risk SLE patients may help institute preventive measures early in the disease course.
与普通人群相比，系统性红斑狼疮（SLE）患者发生急性和慢性心血管疾病的几率更高。本研究对狼疮患者的基线血清进行了全面的代谢组学筛查，以确定在8至9年随访后可预测未来颈动脉斑块进展的代谢物。9名SLE患者无斑块进展，8名SLE患者继而发展为动脉粥样硬化斑块（SLE组），8名患者为无SLE的对照组。与无斑块进展的SLE患者相比，SLE患者的花生四烯酸途径代谢物白三烯B4（LTB4）和5-羟基二十碳四烯酸（5-HETE）以及氧化脂质9/13-羟基十八碳二烯酸（HODE）有显著变化（<0.05且变化倍数>2）。与非SLE对照组相比，SLE患者的支链氨基酸（BCAA）代谢物和缩醛磷脂水平也有显著变化。结合关于这些代谢物的丰富文献，这些发现表明，所鉴定的代谢物不仅可能是SLE患者心血管疾病发展的预后指标，还可能是动脉粥样硬化形成的活跃驱动因素。早期识别这些高危SLE患者可能有助于在疾病进程早期采取预防措施。
